Ascentage Pharma

Ascentage Pharma is a clinical-stage biotech with a unique focus on restoring apoptosis in cancer cells through a portfolio of novel small molecule inhibitors. Its pipeline includes candidates targeting Bcl-2, Bcl-2/Bcl-xL, IAP, and MDM2-p53 pathways, as well as next-generation TKIs, with multiple assets in international registrational trials. The company actively seeks global partnerships to accelerate development and commercialization. With a deep scientific foundation and a late-stage clinical pipeline, Ascentage aims to address significant unmet needs in oncology.

Proprietary drug discovery platform focused on designing small molecule therapies that target key regulators of apoptosis (programmed cell death), including the Bcl-2 family, IAP proteins, and the MDM2-p53 pathway.

Ascentage competes in the apoptosis space with major players like AbbVie (venetoclax) and several biotechs developing Bcl-2/xL, IAP, and MDM2-p53 inhibitors. Its differentiation lies in having the only clinical pipeline targeting all three key apoptotic regulator classes and developing next-generation TKIs like olverembatinib for resistant cancers.